In September 2024, we had a precious encounter with Professor Arieh Warshel, the chief scientist of MoMed Biotech, a member of the National Academy of Sciences of the United States and the winner of the 2013 Nobel Prize in Chemistry. Professor Warshel personally visited MoMed Biotech and had in-depth exchanges with the research and development team to understand the latest progress of research and development projects and gave highly professional guidance.

In September 2024, Bai Chen's team from MoMed Biotech published a research paper titled "Exploring the Activation Process of the Glycine Receptor" online in the journal JACS. This study not only helps us deeply understand the activation mechanism of the glycine receptor (GlyR), a potential therapeutic target for alleviating chronic pain, predicts and validates important mutation sites, but also opens up a new way for developing more effective treatment regimens.

In May 2024, Professor Wu Dongdong from the Biomedical Engineering College at Sichuan University and the MoMed Biotech team led by Bai Chen published a research paper titled "Multi-Responsive Peptide-Based Ultrathin Nanosheets Prepared by a Horizontal Monolayer Assembly" in Angew. Chem. Int. Ed. This work not only sets a new thickness record for peptide-based nanomaterials but also provides new ideas for functionalizing and intelligentizing 2D materials.

Recently, MoMed Biotech, in collaboration with Professor Wu Song's team from Shenzhen University, has developed a molecular generation model called InterDiff based on hotspots residues and interaction cues. This research was published in the top journal in the field of bioinformatics, Briefings in Bioinformatics. InterDiff utilizes a diffusion model as its core architecture and employs the technique of cue learning to guide the generation process of molecules, specifically targeting interactions with protein pocket residues.

Recently, MoMed Biotech's R&D team announced the first batch of activity and animal experiment data for the breast cancer PROTAC pipeline. The initial results obtained from the research, which was designed using MoMed Biotech's MechGen multidimensional intelligent technology platform, indicate that the PROTAC protein degrader molecule CZ-501, which targets ER degradation, performs excellently in terms of both efficacy and safety, with its activity and other indicators reaching the best level in the industry.

The emergence of variants of the SARS-CoV-2 virus poses challenges to the effectiveness of currently available vaccines and therapeutic antibodies. The research group led by Professor Bai Chen has analyzed the impact of mutations on the binding affinity between the spike protein of the novel coronavirus and neutralizing antibodies, antibodies from recovered patients, and artificially designed antibody mimetics by calculating changes in binding free energy. The study evaluates the differences between target sites on the spike protein for several antibodies. The results provided in this paper ma

The Bai Chen Research Group Publishes Paper in the Biology Journal: "Explaining the Structure-Function Relationship of Three Types of G-Protein-Coupled Receptors from an Energetic Perspective"

"In recent years, traditional drug design has required extensive research time and development costs. Computational methods have been widely used to enhance the efficacy and effectiveness of drug discovery and pipelines, leading to the approval of numerous new drugs. The White Morning Research Group published a review article in the International Journal of Molecular Sciences, focusing on the application and challenges of computational methods in assisting drug target identification, lead compound discovery, and optimization."